Edition:
United Kingdom

Novocure Ltd (NVCR.OQ)

NVCR.OQ on NASDAQ Stock Exchange Global Select Market

24.65USD
20 Apr 2018
Change (% chg)

$-0.35 (-1.40%)
Prev Close
$25.00
Open
$24.85
Day's High
$25.50
Day's Low
$24.55
Volume
223,726
Avg. Vol
189,208
52-wk High
$25.65
52-wk Low
$10.50

Select another date:

Fri, Apr 20 2018

BRIEF-Novocure Says Executive Chairman William Doyle's FY 2017 Total Compensation Was $23.8 Mln

* NOVOCURE LTD SAYS EXECUTIVE CHAIRMAN WILLIAM DOYLE'S FY 2017 TOTAL COMPENSATION WAS $23.8 MILLION - SEC FILING Source : https://bit.ly/2HiWTxC Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Novocure Reports Positive Top-Line Results From Stellar Phase 2 Pilot Trial In Mesothelioma

* NOVOCURE REPORTS POSITIVE TOP-LINE RESULTS FROM STELLAR PHASE 2 PILOT TRIAL IN MESOTHELIOMA

BRIEF-NCCN Guidelines Recommend Novocure's Optune In Combination With Temozolomide

* NCCN GUIDELINES RECOMMEND OPTUNE IN COMBINATION WITH TEMOZOLOMIDE AS A CATEGORY 1 TREATMENT FOR NEWLY DIAGNOSED GLIOBLASTOMA

BRIEF-Novocure Ltd Reports Qtrly Net Loss Per Ordinary Share Of $0.12

* Q4 EARNINGS PER SHARE VIEW $-0.11, REVENUE VIEW $53.5 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Novocure Secures New $150 Mln Non-Dilutive Term Loan Financing

* NOVOCURE SECURES NEW $150 MILLION NON-DILUTIVE TERM LOAN FINANCING

BRIEF-Novocure Announces Q4 And FY17 Operating Statistics And Preliminary Revenue

* NOVOCURE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 OPERATING STATISTICS AND PRELIMINARY REVENUE

BRIEF-Novocure Receives FDA IDE Approval For Its PANOVA 3 Phase 3 Pivotal Clinical Trial In Advanced Pancreatic Cancer

* NOVOCURE RECEIVES FDA IDE APPROVAL FOR ITS PANOVA 3 PHASE 3 PIVOTAL CLINICAL TRIAL IN ADVANCED PANCREATIC CANCER

BRIEF-Novocure Receives Reimbursement Approval For Optune In Japan For Treatment Of Glioblastoma

* NOVOCURE RECEIVES REIMBURSEMENT APPROVAL FOR OPTUNE® IN JAPAN FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

BRIEF-Novocure reports qtrly ‍loss per share $0.13​

* Novocure Ltd - ‍Q3 2017 net revenues of $50.1 million, reflecting 131 percent growth versus Q3 2016​ Source text for Eikon: Further company coverage:

Select another date: